“Global Biosimilars And Follow-On Biologics Drugs market set to grow at CAGR of 7.1% by 2025” says new Visiongain report

30 April 2020
Pharma

Visiongain has launched a new pharma report Global Biosimilars and Follow-On Biologics Market 2020-2030: Monoclonal Antibodies (mAbs), Fusion Proteins, Insulin, Erythropoietin’s, Granulocyte Colony-Stimulating Factor (G-CSF), Interferons, Growth Hormones, Fertility Hormones, Blood Disorders, Growth Hormone Deficiency, Autoimmune Diseases, Cancer, Diabetes, Infectious Diseases.

Many blockbusters branded innovator drugs are losing patent protection in the coming years. Some have already lost the market exclusivity and hence are prone to share their market space with the generic versions. Some examples include Roche’s Herceptin and Avastin, Amgen’s Enbrel, AbbVie’s Humira, etc. Billions of dollars are at stake for the branded pharmaceuticals market. This has led to a strong push for the biosimilar manufacturers. As such, both established and local pharmaceutical and biotechnology companies are making their way in this potential market.

The lead analyst of the report commented "As mentioned above, rapid growth in the biosimilars market during the period 2020-2030 will be a driven by a wide range of different factors. This will be primarily driven by the demand for lower cost alternatives to biologics by patients, doctors, healthcare payers and nations. Patent expiries for leading branded biologics will allow for the launch of a wider range of biosimilars in both developed and emerging markets."

Leading companies featured in the report include Amgen Inc, Biocon Limited, Celltrion Healthcare Co. Ltd, Dong-A Socio Holdings Co. Ltd, Dr.Reddy's Labs (DRL), F. Hoffmann-La Roche Ltd. and others.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Cancer Diagnostics Market Report 2021-2031

Major investments have been made by companies in the cancer diagnostics industry in the past few years to develop novel tests to capitalize on the opportunities in the untapped market.

19 April 2021

Read

Visiongain Publishes Food for Special Medical Purpose (FSMP) Market Report 2020-2030

The food for special medical purpose (FSMP) market growth can be attributed to the growing prevalence of metabolic diseases, growing consumer unhealthy lifestyle, and surge in demand from emerging economies such as Asia Pacific, Middle East & Africa, Latin America, and others.

12 April 2021

Read

Visiongain Publishes Cell-Based Assays Market Report to 2030

Growing incidence of chronic diseases; increasing R&D investment for drug discovery research and Growing Adoption of High-Throughput Screening Methodologies are some of the major factors that propel the market growth.

09 April 2021

Read

Visiongain Publishes Cancer Biologics Therapies Market Report 2021-2031

The main drivers for the growth include technological advancements in the development of novel biomarkers, rising preference for minimally or less invasive surgeries, increasing cancer awareness leading to growth in cancer cases, and growing disposable income in emerging economies.

06 April 2021

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever